CODA Biotherapeutics is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform for the treatment of many disorders and diseases. The company is using a revolutionary chemogenetics-based technology to modulate the activity of pathological cells.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/13/18 | $19,000,000 | Series A |
Astellas Venture Management MPM Capital  Novartis Versant Ventures | undisclosed |
| 11/05/19 | undisclosed | Series A Extension |
Astellas Venture Management MPM Capital Versant Ventures | undisclosed |
